Millipore Sigma Vibrant Logo

538285 Glucosylceramide Synthase Inhibitor, Genz-123346 - CAS 491833-30-8 - Calbiochem

Glucosylceramide Synthase Inhibitor, Genz-123346 - CAS 491833-30-8 - Calbiochem: のSDS（安全データシート）、CoA（試験成績書）およびCoQ（品質証明書）、カタログなど製品関連の技術資料を入手いただけます。

同義語: (1R,2R)-nonanoic acid[2-(2ʹ,3ʹ-dihydro-benzo [1, 4] dioxin-6ʹ-yl)-2-hydroxy-1-pyrrolidin-1-ylmethyl-ethyl]-amide, GL1 synthase Inhibitor, Genz-123346, Genz123346

Primary Target: glucosylceramide synthase
View This Product on Sigma-Aldrich
538285
価格＆在庫状況を照会

概要

Replacement Information

主要スペック表

CAS #Empirical Formula
491833-30-8C₂₄H₃₈N₂O₄

価格＆在庫状況

カタログ番号 在庫状況包装 Qty/Pk 価格 数量
5.38285.0001
在庫状況検索中…
—
現在国内在庫なし 現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

      		 ｶﾞﾗｽﾋﾞﾝ 10 mg
      価格を検索中…
      価格が見つかりません
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      弊社照会 詳細を表示　
      値引
      ()
       
      —
      弊社照会
      		 —
      Description
      OverviewA cell-permeable, orally bioavailable fatty acid amide derivative that acts as a highly potent and specific inhibitor of Glucosylceramide Synthase (GL1 synthase; IC50 = 14 nM for ganglioside GM1 inhibition). Does not affect the activities of other related glycosidase, such as 1-O-acylceramide synthase, a-glucosidase, and glucocerebrosidase in any significant manner. Shown to improve glucose tolerance, improve insulin sensitivity, and normalize hemoglobin A1C levels in Zucker diabetic fatty rats (75 mg/kg/day, p.o. for 6 weeks). Also acts as an inhibitor of GlcCer synthase and blocks the conversion of ceramide to GlcCer in murine models that are orthologous to human autosomal dominant polycystic kidney disease and nephronophthisis. Diminishes Akt-mTOR signaling by reducing phosphorylation of Akt and ribosomal S6 kinase in HEK293T cells without affecting their total levels.

      Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water.
      Catalogue Number538285
      Brand Family Calbiochem®
      Synonyms(1R,2R)-nonanoic acid[2-(2ʹ,3ʹ-dihydro-benzo [1, 4] dioxin-6ʹ-yl)-2-hydroxy-1-pyrrolidin-1-ylmethyl-ethyl]-amide, GL1 synthase Inhibitor, Genz-123346, Genz123346
      References
      ReferencesShen, W., et al. 2014. J. Neurochem. 129, 884.
      Natoli, T.A., et al. 2010. Nat. Med. 16, 788.
      Zhao, H., et al. 2007. Diabetes. 56, 1210.
      Product Information
      CAS number491833-30-8
      FormWhite to off-white solid
      Hill FormulaC₂₄H₃₈N₂O₄
      Chemical formulaC₂₄H₃₈N₂O₄
      ReversibleY
      Quality LevelMQ100
      Applications
      Biological Information
      Primary Targetglucosylceramide synthase
      Primary Target IC<sub>50</sub>14 nM for ganglioside GM1 suppression
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient, Blue Ice or Dry Ice
      Toxicity Standard Handling
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      カタログ番号 GTIN
      5.38285.0001 04054839119569

      Documentation

      Glucosylceramide Synthase Inhibitor, Genz-123346 - CAS 491833-30-8 - Calbiochem (M)SDS

      タイトル

      英語版製品安全データシート（(M)SDS） 

      参考資料

      参考資料の概要
      Shen, W., et al. 2014. J. Neurochem. 129, 884.
      Natoli, T.A., et al. 2010. Nat. Med. 16, 788.
      Zhao, H., et al. 2007. Diabetes. 56, 1210.
      データシート

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision28-July-2017 JSW
      Synonyms(1R,2R)-nonanoic acid[2-(2ʹ,3ʹ-dihydro-benzo [1, 4] dioxin-6ʹ-yl)-2-hydroxy-1-pyrrolidin-1-ylmethyl-ethyl]-amide, GL1 synthase Inhibitor, Genz-123346, Genz123346
      DescriptionA cell-permeable, orally bioavailable fatty acid amide derivative that acts as a highly potent and specific inhibitor of Glucosylceramide Synthase (GL1 synthase; IC50 = 14 nM for ganglioside GM1 inhibition). Does not affect the activities of other related glycosidase, such as 1-O-acylceramide synthase, a-glucosidase, and glucocerebrosidase in any significant manner. Shown to improve glucose tolerance, improve insulin sensitivity, and normalize hemoglobin A1C levels in Zucker diabetic fatty rats (75 mg/kg/day, p.o. for 6 weeks). Also acts as an inhibitor of GlcCer synthase and blocks the conversion of ceramide to GlcCer in murine models that are orthologous to human autosomal dominant polycystic kidney disease and nephronophthisis. Diminishes Akt-mTOR signaling by reducing phosphorylation of Akt and ribosomal S6 kinase in HEK293T cells without affecting their total levels.
      FormWhite to off-white solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number491833-30-8
      Chemical formulaC₂₄H₃₈N₂O₄
      Purity≥98% by HPLC
      SolubilityDMSO (50 mg/ml)
      Storage Protect from light
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesShen, W., et al. 2014. J. Neurochem. 129, 884.
      Natoli, T.A., et al. 2010. Nat. Med. 16, 788.
      Zhao, H., et al. 2007. Diabetes. 56, 1210.